Ex-Biopure CEO Settles Blood Substitute Case

Law360, New York (February 21, 2007, 12:00 AM EST) -- Biopure Corp.’s former chief executive has resolved allegations that the pharmaceutical company continued to paint a rosy picture of its blood substitute awaiting approval, despite receiving negative feedback from U.S. federal regulators over the product’s safety.

Former CEO Thomas Moore agreed to shell out a $120,000 civil fine to settle charges that the company misled the public about its efforts to win Food and Drug Administration approval for its main product, Hemopure, according to the U.S. Securities and Exchange Commission on Wednesday.

Moore resolved the matter...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.